R&D News | pharmaphorum

News

Ex-Jazz, Sunesis exec Swisher takes over at NodThera

Anglo-US biotech NodThera has named former Jazz Pharma executive Dan Swisher as its new chief executive, replacing Alan Watt, who will take on the dual roles of president

News

Nippon Shinyaku’s DMD drug fails confirmatory trial

The future of Nippon Shinyaku’s Duchenne muscular dystrophy (DMD) therapy Viltepso has been thrown into doubt after it failed a clinical trial designed to upgrade its 2020

News

FDA sets date for Sarclisa in first-line multiple myeloma

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

ASCO: Merus bispecific garners attention after abstract drop

Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petosemtamab in he

Ex-Jazz, Sunesis exec Swisher takes over at NodThera

Nippon Shinyaku’s DMD drug fails confirmatory trial

FDA sets date for Sarclisa in first-line multiple myeloma

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

ASCO: AffyImmune claims a first with CAR-T for solid tumours

ASCO: Merus bispecific garners attention after abstract drop

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

News

Editor's Picks